Context Therapeutics is trading at $0.32, up 5.33% on October 1, with no clear company-specific catalyst identified. - The gain follows six consecutive declining sessions, including a September 30 close of $0.30. - Its investor-relations press-release page lists September 9 as the latest announcement, with no October 1 release shown. Broad market indicators are modestly higher, but do not clearly explain the move.